PROVAYBLUE
Drug
Provepharm Inc.
Total Payments
$950,658
Transactions
26
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $109,438 | 7 | 0 |
| 2022 | $680,958 | 9 | 0 |
| 2021 | $160,262 | 10 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $950,108 | 25 | 99.9% |
| Consulting Fee | $550.00 | 1 | 0.1% |
Payments by Type
Research
$950,108
25 transactions
General
$550.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PVP-2016005 | Provepharm Inc. | $752,496 | 0 |
| Prospective Registry | Provepharm Inc. | $82,950 | 0 |
| PVP2016005 | Provepharm Inc. | $74,389 | 0 |
| MB imPRoves outcomes in PatieNTS with COVID-19 (BLUEPRINT) | Provepharm Inc. | $27,338 | 0 |
| MB improves outcomes w/patients with Covid 19 | Provepharm Inc. | $4,613 | 0 |
| PVP2016003 | Provepharm Inc. | $2,431 | 0 |
| PVP-2016003 | Provepharm Inc. | $1,788 | 0 |
| PVP20160003 | Provepharm Inc. | $1,560 | 0 |
| MB as 3rd line Vasopressor in Septic Shock | Provepharm Inc. | $1,350 | 0 |
| PVP-22IC04 | Provepharm Inc. | $1,125 | 0 |
| PVP-2016-0005 | Provepharm Inc. | $69.90 | 1 |
Ad
Manufacturing Companies
- Provepharm Inc. $950,658
Product Information
- Type Drug
- Total Payments $950,658
- Total Doctors 2
- Transactions 26
About PROVAYBLUE
PROVAYBLUE is a drug associated with $950,658 in payments to 2 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Provepharm Inc..
Payment data is available from 2021 to 2023. In 2023, $109,438 was paid across 7 transactions to 0 doctors.
The most common payment nature for PROVAYBLUE is "Unspecified" ($950,108, 99.9% of total).
PROVAYBLUE is associated with 11 research studies, including "PVP-2016005" ($752,496).